4.6 Review

Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms

Journal

FRONTIERS IN NEUROSCIENCE
Volume 17, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fnins.2023.1081938

Keywords

Alzheimer's disease; amyloid-beta; tau protein; oxidative stress; neuroinflammation; acetylcholine; mechanisms

Categories

Ask authors/readers for more resources

Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by tau pathology and accumulation of amyloid-beta (Aβ). Aβ aggregation leads to oxidative stress, inflammatory cascade, and caspase activation, causing hyperphosphorylation of tau protein and formation of neurofibrillary tangles (NFTs). Acetylcholine degradation is accelerated, resulting in neurotransmitter deficiency and cognitive impairment. AD research is necessary to identify novel compounds for treatment and prevention, including those targeting Aβ, tau, neurotransmitter modulation, neuroinflammation, neuroprotection, and cognition enhancement.
Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by tau pathology and accumulations of neurofibrillary tangles (NFTs) along with amyloid-beta (A beta). It has been associated with neuronal damage, synaptic dysfunction, and cognitive deficits. The current review explained the molecular mechanisms behind the implications of A beta aggregation in AD via multiple events. Beta (beta) and gamma (gamma) secretases hydrolyzed amyloid precursor protein (APP) to produce A beta, which then clumps together to form A beta fibrils. The fibrils increase oxidative stress, inflammatory cascade, and caspase activation to cause hyperphosphorylation of tau protein into neurofibrillary tangles (NFTs), which ultimately lead to neuronal damage. Acetylcholine (Ach) degradation is accelerated by upstream regulation of the acetylcholinesterase (AChE) enzyme, which leads to a deficiency in neurotransmitters and cognitive impairment. There are presently no efficient or disease-modifying medications for AD. It is necessary to advance AD research to suggest novel compounds for treatment and prevention. Prospectively, it might be reasonable to conduct clinical trials with unclean medicines that have a range of effects, including anti-amyloid and anti-tau, neurotransmitter modulation, anti-neuroinflammatory, neuroprotective, and cognitive enhancement.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available